OraSure Technologies (NASDAQ:OSUR) was downgraded by investment analysts at TheStreet from a “b” rating to a “c+” rating in a research note issued to investors on Thursday.
Other research analysts have also recently issued research reports about the company. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday. Stephens cut OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research report on Monday, July 16th. Zacks Investment Research cut OraSure Technologies from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Raymond James restated a “mkt perform” rating on shares of OraSure Technologies in a research report on Tuesday, October 23rd. Finally, BidaskClub cut OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. OraSure Technologies currently has an average rating of “Hold” and a consensus target price of $20.50.
Shares of OSUR stock traded down $0.19 during mid-day trading on Thursday, reaching $13.01. The stock had a trading volume of 796,704 shares, compared to its average volume of 550,183. OraSure Technologies has a 12-month low of $12.50 and a 12-month high of $22.22. The stock has a market cap of $900.47 million, a P/E ratio of 25.51, a P/E/G ratio of 3.46 and a beta of 1.52.
In related news, Director Charles W. Patrick sold 8,000 shares of OraSure Technologies stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $16.29, for a total transaction of $130,320.00. Following the completion of the sale, the director now owns 54,298 shares in the company, valued at approximately $884,514.42. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.90% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Trexquant Investment LP purchased a new stake in OraSure Technologies during the 3rd quarter worth about $229,000. BlackRock Inc. boosted its stake in OraSure Technologies by 5.9% in the 3rd quarter. BlackRock Inc. now owns 8,979,357 shares of the medical instruments supplier’s stock worth $138,732,000 after buying an additional 498,527 shares during the last quarter. Thomson Horstmann & Bryant Inc. acquired a new stake in OraSure Technologies in the 3rd quarter worth about $439,000. Campbell & CO Investment Adviser LLC acquired a new stake in OraSure Technologies in the 3rd quarter worth about $187,000. Finally, Asymmetry Capital Management L.P. acquired a new stake in OraSure Technologies in the 3rd quarter worth about $2,773,000. Hedge funds and other institutional investors own 92.00% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Read More: Penny Stocks, What You Need To Know
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.